← Eichor
Condition: Oxaliplatin Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Oxaliplatin

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for
Phase 2 · 1 location(s) · Ningbo Medical Center Lihuili Hospital · NCT07542002DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenoca
Phase 3 · 6 location(s) · Akeso · NCT07023315NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06510010Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebreli
Phase 2 · 1 location(s) · The Fourth Affiliated Hospital of Zhejiang University School · NCT06282445A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
Phase 2 · 2 location(s) · Osaka University · NCT05939661XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Phase 2 · 2 location(s) · Case Comprehensive Cancer Center · NCT07146646Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepati
Phase 2 · 7 location(s) · University Hospital, Montpellier · NCT03364530The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life
Phase N/A · 1 location(s) · Turku University Hospital · NCT06551857Feasibility and Benefits of Reflexology in the Prevention of Neuropathy Induced by Oxaliplatin in Colorectal Cancer
NA · 1 location(s) · University Hospital, Toulouse · NCT06251297Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06824883Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
Phase 1/Phase 2 · 5 location(s) · STCube, Inc. · NCT06873763Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04840264Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Ca
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07281768Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the
Phase 2 · 1 location(s) · Jiang Long · NCT06531278Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
NA · 1 location(s) · The University of Texas Health Science Center at San Antonio · NCT07340151The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Can
Phase 1 · 1 location(s) · toqa saad mohammed mohammed · NCT06856447A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or R
Phase 1 · 18 location(s) · Hoffmann-La Roche · NCT06624085Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy
NA · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07558447Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
NA · 1 location(s) · University Hospital, Clermont-Ferrand · NCT07427537Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05768503Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy
Phase 2 · 1 location(s) · National Cancer Institute, Naples · NCT07213557Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Phase 2/Phase 3 · 2 location(s) · Ukrainian Society of Clinical Oncology · NCT06028737Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients
NA · 5 location(s) · GERCOR - Multidisciplinary Oncology Cooperative Group · NCT05850130Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangioca
Phase 2 · 11 location(s) · Memorial Sloan Kettering Cancer Center · NCT04891289A Clinical Study of Arfolitixorin in Patients With mCRC
Phase 1/Phase 2 · 3 location(s) · Isofol Medical AB · NCT06922383Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcin
Phase 2 · 1 location(s) · Northern Jiangsu People's Hospital · NCT07337421Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Phase 2 · 9 location(s) · Rutgers, The State University of New Jersey · NCT05806931
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.